Eloralintide Powder

Eloralintide Powder (LY-3841136) induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium2+ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity.The drug is designed to mimic the function of endogenous amylin, influencing satiety to reduce caloric intake, for the treatment of obesity and type 2 diabetes.

Shaanxi Medibridge supplies 99.6% purity Eloralintide powder for cutting‑edge research. Produced under strict QC with HPLC/MS verification, our RUO-grade Eloralintide (LY-3841136) delivers consistent performance, excellent solubility, and reliable batch-to-batch reproducibility. Customize labeling and formulation on request. Choose Medibridge for trusted quality, responsive service, and dependable results in neuroprotection and neuroplasticity studies.

In Vitro Receptor Pharmacology

A key mechanistic finding is Eloralintide's strong potency in human receptor systems. In a cAMP activation assay, its EC50 at human AMY1R was reported to be approximately 21.2 pM, indicating high in vitro potency and reinforcing its relevance as a targeted amylin-pathway therapeutic candidate.

Mechanistic and Therapeutic Significance

Eloralintide represents a differentiated amylin-based therapeutic strategy designed to preserve anorectic and weight-loss efficacy while potentially improving tolerability through selective receptor activation. Unlike GLP-1–based therapies, it acts by mimicking endogenous amylin physiology, enhancing satiety, delaying gastric emptying, and reducing caloric intake. This distinct mechanism gives Eloralintide important scientific value in obesity research, as it broadens the range of metabolic targets beyond incretin pathways. It may therefore serve not only as an alternative for patients with limited tolerance to GLP-1 therapies, but also as a promising complementary agent in combination-based metabolic treatment strategies.

Eloralintide is well suited for once-weekly dosing because its pharmacokinetic profile supports prolonged systemic exposure in rats, monkeys, and humans. This is particularly valuable for chronic obesity treatment, where adherence, stable drug levels, and long-term manageability strongly influence clinical utility. Its molecular engineering further reinforces this profile: a fatty acid diacid side chain at Lys26 promotes albumin binding, a methylene thioacetal bridge improves chemical stability, and three non-natural amino acids help optimize stability, receptor selectivity, and metabolic performance.

Eloralintide has shown a relatively favorable tolerability profile in both preclinical and early clinical studies. In lean rats, it induced significantly less conditioned taste avoidance than cagrilintide (p < 0.05), suggesting lower aversion-related liability. In a phase 1 single-ascending-dose trial (0.04–12 mg; n = 48), 9 participants reported 16 adverse events, 15 of which were mild. Only 2 participants experienced 4 gastrointestinal events, including 1 moderate vomiting episode.

Phase 1 Proof-of-Concept

In a randomized, placebo-controlled, participant/investigator-blinded, single-ascending-dose Phase 1 study (NCT05295940), Eloralintide was administered at doses ranging from 0.04 to 12 mg in 48 healthy participants with a mean BMI of 27.5 kg/m². Overall, Eloralintide was generally well tolerated. Across Eloralintide-treated cohorts, 9 participants reported 16 adverse events, of which 15 were mild. Gastrointestinal events were limited, with 4 events in 2 participants, including 1 moderate vomiting episode.

Although the primary objective of the study was safety and tolerability, an early pharmacodynamic signal was observed in body weight at Week 4 after a single dose. Mean body weight changed by −2.5% in the 4 mg cohort (p < 0.01 vs placebo) and by −4.4% in the 12 mg cohort (p < 0.001 vs placebo), compared with +0.6% in the placebo group. These findings indicate that Eloralintide demonstrated early biological activity in humans, with a measurable effect on body weight together with a manageable tolerability profile in this Phase 1 setting.